Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists

[Guest guest]

Does this mean that spiro is less effective in women? I don't understand

the part about estrogen's effect.

Val

Am J Physiol Regul Integr Comp Physiol 293: R1754-R1763, 2007. First

published August 1, 2007

WATER AND ELECTROLYTE HOMEOSTASIS

Intact female stroke-prone hypertensive rats lack responsiveness to

mineralocorticoid receptor antagonists

Christiné S. Rigsby,1 E. Burch,1 Safia Ogbi,1 M. Pollock,2 and

Anne M. Dorrance1

1Department of Physiology, and 2Vascular Biology Center, Medical College of

Georgia, Augusta, Georgia

Submitted 28 February 2007 ; accepted in final form 25 July 2007

Data from the Framingham Heart Study suggest that women may be more

sensitive to the deleterious cardiovascular remodeling effects of

aldosterone. Previous studies from our laboratory have shown that chronic

treatment with spironolactone, a mineralocorticoid receptor (MR) antagonist,

decreases ischemic cerebral infarct size and prevents remodeling of the

middle cerebral artery (MCA) in male spontaneously hypertensive stroke-prone

rats (SHRSP). Therefore, we hypothesized that MR antagonism would reduce

ischemic infarct size and prevent MCA remodeling in female SHRSP.

Six-week-old female SHRSP were treated for 6 wk with spironolactone (25 or

50 mg·kg–1·day–1) or eplerenone (100 mg·kg–1·day–1) and compared with

untreated controls. At 12 wk, cerebral ischemia was induced for 18 h using

the intraluminal suture occlusion technique, or the MCA was isolated for

analysis of passive structure using a pressurized arteriograph. MR

antagonism had no effect on infarct size or passive MCA structure in female

SHRSP. To study the potential effects of estrogen, the above experiments

were repeated in bilaterally ovariectomized (OVX) female SHRSP treated with

spironolactone (25 mg·kg–1·day–1). Infarct size and vessel structure in OVX

SHRSP were not different from control SHRSP. Spironolactone had no effect on

infarct size in OVX SHRSP. However, MCA lumen and outer diameters were

increased in spironolactone-treated OVX SHRSP, suggesting an effect of

estrogen. Cerebral artery MR expression, assessed by Western blotting, was

increased in female, compared with male, SHRSP. These studies highlight an

apparent sexual dimorphism of MR expression and activity in the cerebral

vasculature from hypertensive rats.

[Guest guest]

If you are a female stroke prone hypertensive rat (a highly inbred

strain of rat) and your Drs tie off one of the arteries to your brain

for 18 hrs it means that being on spiro does not prevent stroke.

If they take your ovaries and give you spiro out then you still have

strokes but your arteries will look better.

No ovaries means no estrogn.

If you go to theses doctors for a consultation be certain to wear you

white fur coat.

On Apr 13, 2008, at 10:05 AM, Valarie wrote:

> Does this mean that spiro is less effective in women? I don't

> understand

> the part about estrogen's effect.

>

> Val

May your pressure be low!

CE Grim BS, MS, MD

High Blood Pressure Consulting

Specializing in Difficult to Manage High Blood Pressure

Consult the following at for details

bloodpressureline

hyperaldosteronism

[Guest guest]

Very good, Dr. Grim. Some of us are so gullible and naïve, we need you to

tell us what's what.

Val

From: hyperaldosteronism

[mailto:hyperaldosteronism ] On Behalf Of Clarence Grim

If you are a female stroke prone hypertensive rat (a highly inbred

strain of rat) and your Drs tie off one of the arteries to your brain

for 18 hrs it means that being on spiro does not prevent stroke.

If they take your ovaries and give you spiro out then you still have

strokes but your arteries will look better.

No ovaries means no estrogn.

If you go to theses doctors for a consultation be certain to wear you

white fur coat.